PharmacoEconomics & Outcomes News 804, p36 - 2 Jun 2018 Umeclidinium cost effective for COPD in UK Once-daily umeclidinium (UMEC) monotherapy appears to be cost effective for the treatment of chronic obstructive pulmonary disease (COPD) in the UK, according to findings of a GlaxoSmithKline (GSK)- funded study published in Cost Effectiveness and Resource Allocation. The GALAXY COPD disease progression model, populated with data from two 12-week head-to-head GSK trials in patients aged ≥40 years, was used to evaluate the cost effectiveness of umeclidinium compared with tiotropium (TIO) and glycopyrrolate (glycopyrronium; GLY) in patients with COPD, from a UK National Health Service (NHS) perspective over a lifetime time horizon. All drugs were administered once- daily via dry powder inhalers (ELIPTA, Handihaler and Breezhaler, respectively). Umeclidinium was estimated to increase life-years (LYs) and QALYs compared with tiotropium (+0.195 and +0.118, respectively), reduce the number of annual exacerbations (–0.053), and achieve incremental cost savings of £460 per patient. Umeclidinium was therefore dominant compared with tiotropium (more effective and less costly). Umeclidinium was estimated to increase LYs and QALYs compared with glycopyrrolate (+0.124 and +0.101, respectively), and reduce the number of annual exacerbations (–0.033), at an additional cost of £132 per patient, resulting in an incremental cost-effectiveness ratio of £1310 per QALY gained. "UMEC can therefore be considered a dominant treatment option compared to TIO and a cost-effective treatment option compared to GLY. These data may aid ** payers in making judgements on which LAMA treatments can be considered cost-effective in a UK setting," concluded the authors. * 2015/2016 British pounds ** long-acting muscarinic antagonist Shah D, et al. Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation 16: No. 17, 10 May 2018. Available from: URL: https://doi.org/10.1186/s12962-018-0101-3 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804
PharmacoEconomics & Outcomes News – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera